Quarterly Result9 Feb 2026, 07:54 pm
Aurobindo Pharma Reports 8.4% YoY Revenue Growth in Q3FY26
AI Summary
Aurobindo Pharma Limited has announced its consolidated financial results for the quarter ended December 31, 2025. The company reported an 8.4% YoY increase in revenue from operations to INR 8,646 Cr. The US formulations revenue increased by 2.2% YoY to INR 3,739 Cr, while Europe formulations revenue increased by 27.4% YoY to INR 2,703 Cr. The net profit for the period stood at INR 910 Cr. The company has a strong net cash position of USD 251mn and generated free cashflows of $118mn during the quarter.
Key Highlights
- Revenue from Operations increased by 8.4% YoY to INR 8,646 Cr
- US formulations revenue increased by 2.2% YoY to INR 3,739 Cr
- Europe formulations revenue increased by 27.4% YoY to INR 2,703 Cr
- Net Profit for the period stood at INR 910 Cr
- Strong net cash position of USD 251mn and free cashflows of $118mn generated during the quarter